

OncoTherapy Science, Inc.

November 19, 2015

Acceptance of a proposal on our compound for NCL characterization program

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, "OncoTherapy") announces that a proposal by Professor Yusuke Nakamura, our collaborator in The University of Chicago, has been accepted for the United States "NCL characterization" program, regarding the characterization of a small molecule TOPK inhibitor developed by OncoTherapy. The program is provided by the United States National Cancer Institute (NCI), Nanotechnology Characterization Laboratory (NCL). OncoTherapy will provide the compound and related information for the program.

This small molecule compound (the compound reported on October 23rd 2014) strongly inhibits an oncogene product TOPK that has a critical role in cell division of cancer cells. Intravenous administration of a liposomal formulation of the compound caused complete regression of transplanted tumors.

The NCL characterization program will conduct a part of essential experiments that are required for IND application, and is expected to promote the development of the compound.